Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Barnes Retina Institute Pfizer |
---|---|
Information provided by: | Barnes Retina Institute |
ClinicalTrials.gov Identifier: | NCT00272766 |
The purpose of this study is to evaluate the safety and effect on visual acuity of Macugen (pegaptanib sodium) in patients with subfoveal choroidal neovascularization (CNV) secondary to the ocular histoplasmosis syndrome (OHS).
Condition | Intervention |
---|---|
Ocular Histoplasmosis Choroidal Neovascularization |
Drug: pegaptanib sodium |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Macugen for Histoplasmosis-An Open-Label, Single-Site, Comparative, Prospective Case Series |
Estimated Enrollment: | 24 |
Study Start Date: | February 2006 |
Estimated Study Completion Date: | May 2007 |
Ocular histoplasmosis is a leading cause of severe and irreversible central vision loss in middle-aged adults living in the central and eastern US. OHS has been associated with the fungus Histoplasma capsulatum, a dimorphic soil mold found in 18 to 20 states in the central and eastern US. Annually, approximately 100,000 people are thought to be at risk of vision loss caused by OHS. This study will include OHS patients with CNV lesions no larger than 5400 microns in greatest linear diameter with classic or occult CNV extending under the geometric center of the FAZ and best-corrected visual acuity letter score between 20/40-20/200. Twenty four patients will be enrolled and the study will have 2 treatment arms with 12 patients each. The first arm will consist of 12 patients who will receive 0.3 mg of Macugen intravitreally every 6 weeks for one year. The second arm will consist of 12 patients who will receive Photodynamic Therapy (PDT) with Visudyne every 3 months for one year.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Missouri | |
Barnes Retina Institute | |
St. Louis, Missouri, United States, 63110 |
Principal Investigator: | Gaurav K Shah, MD | Barnes Retina Institute |
Study ID Numbers: | 2005-0722, 05-1103 |
Study First Received: | January 4, 2006 |
Last Updated: | October 25, 2006 |
ClinicalTrials.gov Identifier: | NCT00272766 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Ocular histoplasmosis Macugen Photodynamic therapy with Visudyne Best-corrected visual acuity scores between 20/40-20/200 classic or occult choroidal neovascularization |
Mycoses Uveal Diseases Eye Diseases Metaplasia Choroid Diseases |
Histoplasmosis Verteporfin Neovascularization, Pathologic Choroidal Neovascularization |
Mycoses Uveal Diseases Pathologic Processes Eye Diseases Metaplasia |
Choroid Diseases Histoplasmosis Neovascularization, Pathologic Choroidal Neovascularization |